Cefokel (Ceftiofur) is an established third-generation cephalosporin commonly used to address systemic and serious localized bacterial infections in animals, relevant for management during acute stages of disease. Its use is relevant across several primary areas of veterinary medicine, supporting recovery where symptoms are intense.

The antibiotic is applied across conditions presenting with acute episodes, including Bovine Respiratory Disease (BRD), Foot Rot, Acute Postpartum Metritis, and Swine Respiratory Disease (SRD). These clinical situations involve symptoms related to systemic imbalance, such as high fever, severe respiratory distress, and functional mobility impairment. The use is aligned with domains where supportive relief helps ease the overall symptom burden.

“It is considered relevant in supporting comfortable movement and stability, particularly when symptoms interfere with routine activities.”

Quick Fact: Relief for Lameness Cefokel is commonly used to help manage the severe, acute lameness associated with bacterial infections like Foot Rot, contributing to the management of symptoms related to localized discomfort.

Cefokel is a veterinary medicinal product that contains the antibiotic ceftiofur and is authorized exclusively for use in pigs and cattle. Official government regulatory documents define specific populations and conditions where its use is allowed, restricted, or strictly prohibited.

Eligibility and Restrictions

Classification	Status and Population
Allowed Use	Pigs and Cattle for the treatment of specific bacterial infections as directed by a veterinarian.
Conditional Use	Pregnant or lactating sows or cows; use is conditional upon a veterinarian's risk assessment, as safety studies are not fully established for these groups.
Contraindicated Use	Animals with known hypersensitivity to ceftiofur or other beta-lactam antibiotics (penicillins, cephalosporins).
Prohibited Species	Poultry (including eggs) is explicitly prohibited due to the risk of contributing to antimicrobial resistance that could affect human health.
Prohibited Purpose	The medicine must not be used for disease prevention (prophylaxis) or as part of herd health programs, but only for the treatment of active, diagnosed infections.

All use is restricted to veterinary supervision and is generally advised only after specific testing confirms the bacteria's susceptibility to the medicine.

Interactions with Other Medicines and Products

Official government regulatory information for Ceftiofur (the active ingredient in Cefokel) outlines specific interactions related to pharmacodynamic effects and renal elimination pathways. No formal contraindications are listed solely due to interaction risk, and no interactions involving specific metabolic enzymes, food, or alcohol are documented.

---

Documented Interaction Patterns

Interaction Type	Interacting Substance/Class	Official Caution/Restriction
Pharmacodynamic Antagonism	Bacteriostatic antibiotics (e.g., Macrolides, Tetracyclines, Sulfonamides)	Co-administration may antagonize (diminish) the bactericidal effect of Cefokel.
Increased Renal Risk	Potentially nephrotoxic drugs (e.g., Aminoglycosides)	Use with caution due to an increased risk of adverse effects on the kidney.
Altered Clearance	Probenecid	Caution is advised; Probenecid may interfere with the elimination of beta-lactam antibiotics.

---

Population and Administration Context

Specific caution is advised regarding the use of Cefokel in animals with kidney disease (renal impairment) when simultaneously administering nephrotoxic agents, as this population may face a heightened risk of adverse effects. There are no official requirements for separating the administration of Cefokel from other medicines by a specific time interval.

The action of Cefokel is mechanistic and bactericidal, focusing on the molecular architecture of the target pathogen. Its effect is mediated by desfuroylceftiofur (DFC), the active metabolite formed rapidly after administration.

---

Irreversible Inhibition of Cell Wall Synthesis

This domain covers the primary biological target and the resulting cellular cascade. The DFC metabolite functions as an irreversible covalent inhibitor that targets Penicillin-Binding Proteins (PBPs) located on the bacterial cell membrane. By binding to these crucial enzymes, the drug prevents the final transpeptidation step, which is essential for cross-linking the peptidoglycan chains that form the rigid bacterial cell wall. This structural failure leads directly to the Disruption of Bacterial Cell Wall Integrity, causing the bacterium to rupture due to osmotic pressure (lysis), which produces the core bactericidal effect.

---

Evasion of Common Bacterial Resistance

This mechanistic domain highlights a key structural feature. The molecular structure of Cefokel demonstrates stability against the hydrolytic action of many common bacterial beta-lactamase enzymes. This stability allows the active metabolite to remain intact and successfully reach and inhibit the PBPs even in strains that produce these defense enzymes. This domain facilitates the primary inhibitory mechanism against strains that produce these defense enzymes, preserving the drug's intended bactericidal activity.

Official Administration Protocols

Cefokel, containing the active ingredient Ceftiofur, is administered exclusively via parenteral injection, meaning it is never given by the oral route. The specific route is determined by the formulation: short-acting salts (Hydrochloride) and the long-acting Crystalline Free Acid (CFA) are used for intramuscular (IM) or subcutaneous (SC) injection, with the exact approved route varying by species and product label.

Dosing and Frequency

Dosage is strictly weight-based, measured in Ceftiofur equivalents (mg/kg) of body weight. The frequency depends on the formulation type:

• Short-Acting Regimens (e.g., Ceftiofur Hydrochloride): The dose typically ranges from 1.1 to 2.2 mg/kg and is administered once daily (24-hour intervals) for a duration of three consecutive days. Treatment may be extended up to five consecutive days for animals that do not show a satisfactory response to the initial course.
• Long-Acting Regimens (CFA): This formulation is typically given as a single injection at a higher concentration, such as 5.0 mg/kg for swine or 6.6 mg/kg for cattle. A single administration is intended to provide sustained concentrations, with two injections, approximately 72 hours apart, approved for certain indications.

Preparation and Special Conditions

Before administration, suspension formulations must be vigorously shaken to ensure the active ingredient is uniformly dispersed. Specific injection sites are mandated for long-acting formulas, such as the post-auricular region of the neck for swine or the base of the ear for cattle. Usage rules include specific population constraints: the drug is prohibited for use in calves intended for veal production, but is approved for use in lactating dairy cattle under specific regimens.

Research Evidence / Overview of Studies for Cefokel

Evidence for Use in Bovine Respiratory Disease (BRD)

Research has explored the use of Cefokel in studies related to Bovine Respiratory Disease (BRD), which is a condition involving periods of heightened symptoms in cattle. Studies for this indication often involve clinical field studies and regulatory trials that are structured to characterize the drug's performance. These research efforts focus on outcomes related to systemic or functional imbalance, such as whether the animal's fever changes over time and the course of other visible signs of illness.

Studies described patterns in how symptoms evolved in the observed populations during and shortly after the study period. Findings describe patterns observed in the studies related to the need for subsequent antimicrobial treatment and measured functional endpoints. Study outcomes included measured changes in functional measures, such as weight gain and overall activity level.

---

Evidence for Use in Swine Respiratory Disease (SRD)

Cefokel was evaluated in studies related to Swine Respiratory Disease (SRD), another condition associated with acute or disruptive episodes. Research for this indication includes regulatory field studies and dose characterization studies that are structured to characterize the drug's performance. These research efforts focus on outcomes related to systemic imbalance and physiological strain, with research examining changes in mortality rates and scores related to the overall clinical change based on predetermined criteria.

Studies also examined the animals post-mortem; researchers monitored and reported on lung lesion scores, and they also tracked changes in body temperature. Research highlights changes measured during the study period, with outcomes primarily focused on short-term clinical change based on predetermined criteria.

---

What Research Gaps and Uncertainties Remain

The research landscape primarily consists of studies that focus on short-term or episodic symptom patterns and defined time intervals immediately following the study period. This means that while studies provide insight into short-term changes in acute conditions, the durability of the observations is less characterized. The follow-up durations were limited in many core studies, meaning that the full picture regarding long-term outcomes is not fully established. Evidence comparing different treatments in all settings is often lacking, and the sample sizes were modest in certain field studies. Furthermore, data for certain use scenarios or highly specific subgroups remain limited.

Key Studies & References NIH MedlinePlus: Antibiotics - Mechanism of action (General Bactericidal Action)

Common questions about Cefokel (FAQ)

---

Q: What is Cefokel used for?

A: Cefokel is a cephalosporin antibiotic used to treat a variety of bacterial infections. According to regulatory documents, it is indicated for infections in different parts of the body, such as the respiratory tract, urinary tract, and skin. It works by killing the susceptible bacteria that cause these infections.

---

Q: How long does Cefokel take to work?

A: The official product information indicates that Cefokel's effect starts shortly after administration, as the medicine is quickly absorbed by the body. The time it takes to see an improvement in symptoms can vary depending on the type and severity of the infection. Completing the full prescribed course is generally recommended for treatment efficacy.

---

Q: Is Cefokel an injectable or tablet drug?

A: Cefokel is available in forms that can be administered in different ways. The official product labeling includes a powder for solution that can be prepared for injection or infusion. The decision regarding the most appropriate form and route of administration is made by a healthcare professional.

---

Q: What should I do if I miss a dose of Cefokel?

A: Official product information contains specific instructions for managing a missed dose. These instructions typically outline when to take the missed dose and when to skip it if the next dose is due soon, emphasizing that a double dose should be avoided. Patients are advised to refer to the official prescribing information for details.

---

Q: Can children use Cefokel?

A: Official information indicates that Cefokel can be used in pediatric patients (children). However, the appropriate form, dose, and duration of treatment must be specifically determined based on the child's weight and the type of infection being treated. The appropriate use of Cefokel in a child is a decision that must be determined by a qualified healthcare professional.

---

Q: Can I drink alcohol while taking Cefokel?

A: Official regulatory documents do not list a specific interaction between Cefokel and alcohol that would forbid its use. However, alcohol consumption can complicate recovery from an illness while on medication. It is standard practice to consult a healthcare professional regarding alcohol consumption while taking any prescription medication.

---

Q: How should Cefokel be stored?

A: Regulatory documents state that unreconstituted vials of Cefokel powder should be stored at controlled room temperature, which is typically below 25 C (77 F). Once the medicine is mixed into a solution, it has specific requirements, such as refrigeration, and a limited time frame for use. Specific storage instructions, which may include following guidance from a pharmacist, are detailed on the product packaging.

---

Q: What if my symptoms return after finishing Cefokel?

A: Official product information emphasizes the necessity of completing the full prescribed course to successfully treat the infection. If symptoms recur after finishing treatment, this may suggest the infection has not been fully resolved. In this situation, it is important to contact a healthcare provider for a thorough medical evaluation.

Official Storage and Disposal Requirements

Cefokel (Ceftiofur Suspension for Injection) must be stored below 25°C and protected from direct sunlight. It is strictly required that the product must not be allowed to freeze.

The suspension must be stored in its original container, which must be kept tightly closed. Once the container is opened (broached), the product typically has a limited stability period, often 28 days for certain formulations.

For safety, the medicine must be kept out of the sight and reach of children.

Disposal of unused or expired product must be done in accordance with local, regional, and national regulations. To prevent environmental contamination, it is prohibited to discard the medicine into drains, water courses, or onto the ground.